Constipation from GLP-1 Medications: Functional Medicine Solutions for Relief GLP-1 receptor agonists such as semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound) are transforming the treatment of obesity, insulin resistance, and type 2 diabetes
VLEKT is characterized by a very low total energy intake (650800 kcal per day), carbohydrate restriction to less than 30 g/day, fat intake of around 20 g/day with a preference for sources of unsaturated fats such as extra-virgin olive oil, and protein intake of 0.81.2 g/kg of reference body weight (i.e., calculated based on the patient's height) ( MAD was developed in 2003 as an alternative to the conventional KD, particularly in the context of treating drug-resistant epilepsy ( MCTKD was developed in 1971 by Huttenlocher et al
This is exciting as thats the first phase 2 study to explore whether combining a GLP-1 RA with a myostatin/activin inhibitor could boost both the magnitude and quality of weight loss
The FDA asked the industry to nominate substances for inclusion on the list
FAQs Ipamorelin What is CJC-1295 (no DAC) + Ipamorelin Blend
